Osteoporosis drug licensed for women with high fracture risk.
Traynor
Kate
K
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069448:Denosumab; D017277:Drug Approval; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D017698:Postmenopause; D053245:RANK Ligand / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab